Major players in the inhalation sedatives market are AbbVie Inc. , Baxter International Inc. , Fresenius SE amp, Co. KgaA, Halocarbon Products Corporation, Hikma Pharmaceuticals PLC. , Jiangsu Hengrui Medicine Co, Lunan Pharmaceutical Group Co.
New York, Sept. 24, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Inhalation Sedatives Global Market Report 2021: COVID-19 Growth And Change To 2030" - https://www.reportlinker.com/p06151691/?utm_source=GNW
Ltd, Novartis AG, Piramal Enterprises Ltd, and Troikaa Pharmaceuticals Ltd.
The global inhalation sedatives market is expected to grow from $1.28 billion in 2020 to $1.34 billion in 2021 at a compound annual growth rate (CAGR) of 4.7%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $1.62 billion in 2025 at a CAGR of 5%.
The inhalation sedatives market consists of sales of inhalation sedatives by companies who manufacture them.Inhalation sedatives are the drugs used to induce or maintain inhalation sedation, which is a type of conscious sedation where a drug is inhaled to suppress the central nervous system activity so that there is no much stress on the patient during a surgical process or a treatment and responds to the physician commands without protective reflexes.
Inhalation sedatives are used in hospitals, ambulatory surgical centers and other care providing centers.
The inhalation sedatives market covered in this report is segmented by product into sevoflurane, desflurane, isoflurane, nitrous oxide. It is also segmented by application into induction, maintenance and by end-user into hospitals, ambulatory surgical centers, others.
The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Contradictions associated with inhalation sedatives are expected to hinder the market.Inhalation sedatives, although safe most of the time, can rarely result in adverse events.
For instance, inhalation sedatives cannot be used in patients who have undergone a recent ear surgery as they build up pressure in the middle ear.Also, in pregnant women, the use of inhalation sedatives is avoided to minimize the risk of possible toxicity.
Inhalation sedatives affect the foetus by interfering with folic acid absorption in pregnant ladies causing neurotoxicity.Studies show that prolonged exposure to nitrous oxide may cause reproductive and haematological disorders in the operator.
The inhalation sedatives also cannot be used for patients with common cold, nasal blockage, or COPD as they cannot be absorbed by the patient, and therefore do not show the required effect. All these factors are causing a hindrance to the usage of inhalation sedatives and an acceptance of other sedative methods. Therefore, contraindications associated with inhalation sedatives are expected to hinder the market.
The short onset and duration time of inhalation sedative is expected to drive the inhalation sedative market.Rapid onset of inhalation sedative and quick recovery rate makes it applicable for short procedures especially in dental surgeries of paediatrics, and in intensive care units for decreasing the pain and quick recovery.
For instance, the most commonly used inhaled sedative is nitrous oxide, which is administered as a mixture of 30-70% of oxygen, takes about 1-2 minutes to act and the duration of action is 5 minutes.The short time required for the onset of action and its short duration makes nitrous oxide the most used inhalation sedative for dental treatment.
Therefore, the short onset and duration time of inhalation sedatives is expected to drive the inhalation sedatives market.
The production of generic inhalation sedatives is expected to be the new trend in the inhalation sedatives market.Generics are a type of drug that has the same chemical formula, dosage form, dose and effect as that of the patented drug but are produced by the companies when the patent expires.
The generic inhalation sedatives production has increased for the last few years.For instance, in January 2019, Novartis’ division Sandoz has launched a liquid for inhalation called desflurane in the United States, a first generic of an inhalation agent suprane that is used for induction and maintenance in adults and paediatrics.
Health Canada has given a receipt of a drug identification number to Blue-Zone Technologies Ltd that permits it to launch the generic desflurane drug. Therefore, the production of generic inhalation sedatives is expected to become the new trend in the inhalation sedatives market.
The countries covered in the market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.
Read the full report: https://www.reportlinker.com/p06151691/?utm_source=GNW
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
CONTACT: Clare: firstname.lastname@example.org US: (339)-368-6001 Intl: +1 339-368-6001